Physician profile
Robert J Sporter
NPI 1568697191
$945,925.71
in general payments reported to CMS, 2019-2025
41 companies · $253K in 2025
The $253K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $23K · 2021: $43K · 2022: $102K · 2023: $224K · 2024: $244K · 2025: $253K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $569K · Travel and Lodging: $94K · Consulting Fee: $33K · Food and Beverage: $24K · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $568,915.86 |
| Travel and Lodging | $94,162.28 |
| Consulting Fee | $33,380.25 |
| Food and Beverage | $23,879.30 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $466,621.12 | 2019-2025 | Dupixent |
| Genzyme Corporation | $446,051.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $13,978.50 | 2019-2025 | |
| Circassia INC. | $5,880.19 | 2019-2022 | |
| Alk-Abello, INC | $2,834.80 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Astrazeneca Pharmaceuticals Lp | $2,112.91 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,761.37 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan INC. | $1,179.00 | 2020 | |
| Kaleo, INC. | $725.75 | 2019-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $678.65 | 2019-2024 | |
| Optinose US, INC. | $476.15 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.77 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $300.28 | 2023-2025 | Tezspire |
| Neurent Medical Limited | $265.97 | 2023-2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Abbvie INC. | $263.56 | 2022-2025 | Rinvoq |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $234.28 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $230.93 | 2019-2022 | |
| Intersect Ent, INC. | $188.67 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $166.03 | 2025 | Neffy |
| Organon LLC | $161.96 | 2025 | Vtama |
| Incyte Corporation | $149.35 | 2022-2023 | Opzelura |
| Stryker Corporation | $134.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.71 | 2019-2024 | |
| Hikma Pharmaceuticals USA | $108.13 | 2023-2024 | Ryaltris |
| Aerin Medical INC. | $107.42 | 2024-2025 | |
| Medtronic, INC. | $99.39 | 2023-2025 | Pteye Parathyroid Detection System, Sinuva, Stealthstation S8 Platform |
| Genentech USA, INC. | $99.13 | 2019-2023 | Xolair |
| Leo Pharma INC. | $98.92 | 2022 | |
| Aimmune Therapeutics, INC. | $92.68 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $82.31 | 2019 | |
| Smith+Nephew, INC. | $55.53 | 2022-2023 | Rapid Rhino, Tula, Coblation |
| Spirair, INC. | $54.22 | 2025 | |
| Dermavant Sciences, INC. | $44.59 | 2024 | Vtama |
| Phadia US INC. | $34.21 | 2020-2024 | Immunocap |
| Integra Lifesciences Corporation | $24.97 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Phathom Pharmaceuticals, INC. | $22.49 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $21.15 | 2023 | |
| Acclarent, INC | $21.04 | 2019 | |
| Shire North American Group INC | $17.91 | 2019 | |
| Grifols USA, LLC | $16.97 | 2021 | |
| Octapharma USA, INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sporter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.